Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

ABSTRACT:

Abstract background

Monoclonal antibodies have become attractive clinical anti-cancer drugs in the last 3 decades due to their targeting specificity and suitable pharmacokinetic properties. Mesothelin is a tumor-associated antigen with limited expression in normal tissues. It is frequently over-expressed on the cell membrane of a number of epithelial malignancies (e.g. mesothelioma, pancreatic, ovarian, lung, triple negative breast and gastric cancers).

Methods

Mesothelin is validated as a suitable antibody target for cancer therapy. A number of novel antibody therapeutics targeting mesothelin in development are compared and their mechanisms of action are also discussed. Both basic science and clinical data are provided to give a complete veiw of how an agent is developed fr

SUBMITTER: Zhao XY 

PROVIDER: S-EPMC5080863 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature